Treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) leads to rapid and sustained tumor shrinkage in a subset of patients with non–small cell lung cancer (NSCLC) [1]–[3]. The gene discussed is EGFR; the disease is lung cancer.